Literature DB >> 9541025

Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts.

B S Verbeek1, S S Adriaansen-Slot, T M Vroom, T Beckers, G Rijksen.   

Abstract

Overexpression of EGFR and c-erbB2 frequently occurs in human breast cancers, correlating with poor prognosis. Here we show that overexpression of EGFR and c-erbB2 in cell lines increases cell migration, an important step in metastasis formation. The effect of EGFR on migration is dependent on the addition of EGF to the cells. In contrast, c-erbB2 seems to act independently of its ligand in these assays. Overexpression of this receptor is sufficient to induce cell migration. In addition, we investigated the involvement of a number of signal transduction pathways known to be activated by the EGFR. We found that inactivation of MAPKK results in a decreased migration, while inactivation of PI3K increases migration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541025     DOI: 10.1016/s0014-5793(98)00224-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  40 in total

1.  Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusions.

Authors:  Brian D Harms; Gina M Bassi; Alan Rick Horwitz; Douglas A Lauffenburger
Journal:  Biophys J       Date:  2005-02       Impact factor: 4.033

2.  Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Authors:  Toni M Brand; Emily F Dunn; Mari Iida; Rebecca A Myers; Kellie T Kostopoulos; Chunrong Li; Chimera R Peet; Deric L Wheeler
Journal:  Cancer Biol Ther       Date:  2011-09-01       Impact factor: 4.742

3.  The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein.

Authors:  Hongbing Li; Juan Sánchez-Torres; Alan Del Carpio; Valentina Salas; Antonio Villalobo
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

4.  Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).

Authors:  Maria D Corte; Juan A Rodil; Julio Vázquez; Lucia García; Juan C Rodríguez; Miguel Bongera; José C Fernández; Luis O González; Ma Luz Lamelas; Maite Allende; José L García-Muñiz; Antonio Fueyo; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

5.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Authors:  Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase.

Authors:  Poonam R Molli; Liana Adam; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

7.  Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4.

Authors:  Patricia A Cronin; Jiang H Wang; H Paul Redmond
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

8.  Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.

Authors:  Vineet Sangar; Cory C Funk; Ulrike Kusebauch; David S Campbell; Robert L Moritz; Nathan D Price
Journal:  Mol Cell Proteomics       Date:  2014-07-05       Impact factor: 5.911

9.  Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model.

Authors:  A Roetger; A Merschjann; T Dittmar; C Jackisch; A Barnekow; B Brandt
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.

Authors:  Michael H Tomasson; Zhifu Xiang; Richard Walgren; Yu Zhao; Yumi Kasai; Tracie Miner; Rhonda E Ries; Olga Lubman; Daved H Fremont; Michael D McLellan; Jacqueline E Payton; Peter Westervelt; John F DiPersio; Daniel C Link; Matthew J Walter; Timothy A Graubert; Mark Watson; Jack Baty; Sharon Heath; William D Shannon; Rakesh Nagarajan; Clara D Bloomfield; Elaine R Mardis; Richard K Wilson; Timothy J Ley
Journal:  Blood       Date:  2008-02-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.